BridgeMD
COMPASS - COpenhagen MenoPAuSe Study
EU CTIS ID: 2025-522558-37-00
What this study is testing
A randomized single-blinded 8 weeks clinical trial with four parallel groups comparing the effect of an gonadotropin releasing hormone(GnRH)-analog, transdermal estrogen or transdermal testosterone to placebo on change in bone markers in postmenopausal women.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Women >40 years and ≤65 at screening visit
- A body mass index between 18-35
- Confirmed menopause
- Moderate to severe vasomotor symptoms (VMS)
You likely can't join if
- Negative urine hCG test
- Previous thromboembolic event
- The use of opioids, anticoagulating treatment or unwilling to pause fish oil/Omega-3 supplements 3 days prior visit 1 and 3
- Current alcohol or drug abuse
- Hypertension treated with more than one drug
- Severe history of allergy, hypersensitivity, or intolerance to drugs
See the full eligibility criteria
- Women >40 years and ≤65 at screening visit
- A body mass index between 18-35
- Confirmed menopause
- Moderate to severe vasomotor symptoms (VMS)
- Negative urine hCG test
- Previous thromboembolic event
- The use of opioids, anticoagulating treatment or unwilling to pause fish oil/Omega-3 supplements 3 days prior visit 1 and 3
- Current alcohol or drug abuse
- Hypertension treated with more than one drug
- Severe history of allergy, hypersensitivity, or intolerance to drugs
- Moderate to severe liver and kidney disease
- Diagnosed with type 1 or 2 diabetes
- Chronic diseases requiring immunomodulatory treatments such as rheumatoid arthritis, inflammatory bowel disease, and vasculitis etc.
- Known uterine fibroids, Endometriosis, Systemic lupus erythematosus (SLE), otosclerosis, migraine or sleep apnea
- Known Epilepsy or previous seizures or convulsive disorder
- Current or previous hormone replacement therapy
- Current or previous cancer diagnosis
- Known BRCA gene mutation
- Current or previous thyroid disease
- Osteoporosis
- Major psychiatric diagnosis including ongoing medication e.g. selective serotonin re-uptake inhibitors (SSRIs)
- Known prolonged QT or other known clinically significant abnormal ECG, including taking medication that can prolong QT interval (eg. sotalol, dronedarone, amiodarone, methadone, and several antipsychotic drugs)
- Previous myocardial infarction or heart failure
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.